Diminishing returns, quantified
The ceiling in this class is anatomical: the same receptor populations that suppress appetite provoke nausea, and they saturate together.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 31 of 170 of this archive, newest first.
The ceiling in this class is anatomical: the same receptor populations that suppress appetite provoke nausea, and they saturate together.
What the pharmacokinetic data supports about dose timing, missed doses and interruption.
Four independent services underpin confidence in this market. All four are competent at chemistry. Microbiology is a different accreditation, a different facility and a…
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Efficacy was never the question in this appraisal. Duration of treatment was.
Reported from the sessions, and from the two hours afterwards.
Dead space in the needle hub is a real and calculable loss, and it matters more at small volumes than anybody expects.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Efficacy was never the question in this appraisal. Duration of treatment was.
The observation that closes a facility is rarely the dramatic one.
The evidence base is thin and the document says so, which is to its credit.
The condition on arrival is recorded by some services and not others, and it is one of the more informative lines in a report.
The Journal’s standing position: a mass that matches is necessary evidence of identity and nowhere near sufficient.
Reported from the analysis, not from a warning notice.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The evidence base is thin and the document says so, which is to its credit.
Reported from the sessions, and from the two hours afterwards.
The intervention with the clearest evidence is the one nobody frames as an intervention: adjusting the dose.
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The document is four pages. Three of them are about dates.
A proper account of an operation that existed, and of what closing it cost.
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
Every step between the laboratory report and the product page removes information, and the badge is the last step.
The route did not close because of a rule about peptides.
The document is four pages. Three of them are about dates.
A proper account of an operation that existed, and of what closing it cost.
Reported from the analysis, not from a warning notice.
HbA1c integrates roughly three months of glycaemia with the most recent weeks weighted most heavily. Almost every misreading of it is a misreading of that weighting.
Almost every figure in circulation about tolerability comes from six publications. This is what they say.